NEW HEMOFARM PREPARATIONS TO APPEAR SOON
NEW HEMOFARM PREPARATIONS TO APPEAR SOON
NEW HEMOFARM PREPARATIONS TO APPEAR SOON
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
active component, the great proportion of the active component in the tablet mass. Following successful selection of the<br />
most optimum formulation and production technique based on laboratory research, and followed by stability results,<br />
research was conducted also of the bioequivalence of the dose of 100 mg. In vitro and in vivo tests proved that our<br />
product was bioequivalent with the originator, under the patented name Cozaar, more precisely with the product<br />
registered on the German market under the name Lorzaar film tablets of the producer Merck Sharp & Dohme.<br />
The following diagram shows the results of the in vitro tests of the release of the active component for our and the original<br />
product:<br />
The efficiency, safety and quality of our generic product<br />
has been confirmed through all development phases by<br />
excellent results in the physical-chemical and biologicalmedical<br />
researches. The trend of such good results<br />
continued in the first transfer phase in the production, so<br />
that we expect positive opinions and release of the first<br />
batch by the Agency for Medicaments.<br />
Hemofarm Institute<br />
Staša Vuković<br />
New Product Development Project Manager<br />
R&D Department<br />
STADA R&D MEETING IN VRŠAC<br />
35 representatives of all business units of the STADA group stayed in Vršac from September 17 to 19 in the aim of<br />
attending the regular half-yearly R&D meeting, which was held in hotel Villa Breg and was hosted by our company.<br />
Considering the significance of the meeting at which the production portfolio was defined for the whole STADA group, our<br />
president Mr. Miodrag Babić, vice-president Mr. Nikola Stanković and the executive vice-president Miss Sonja Pejović<br />
took also part. Mr. Babić made a statement to the attendants at the very beginning of the meeting, wishing them welcome<br />
and successful work and then he made a brief presentation about Hemofarm. Our president pointed out that Hemofarm<br />
was a company in which medicaments were developed and produced to be distributed throughout Europe and he invited<br />
the participants to visit our plants on the second day so as to get assured about the good equipment in all of our plants and<br />
laboratories, but also about the expertise and competence of our staff.<br />
Mr. Christof Schumann, member of the STADA group board and the R&D directors Miss Sigrid Dienel and Mr. Michael<br />
Wolf-Pflugmann presided over the working part of the meeting. Consideration was given to the status of the earlier defined<br />
development projects and new projects were proposed during the whole day of work. It was maintained once again that<br />
under the conditions of the ever increasing market competition there is a great pressure on the R&D, which must provide<br />
new products using the available resources, but also strategic approaches. It was pointed out that STADA got<br />
development facilities with the acquisition of Hemofarm, which will enable more and more new products to be developed<br />
in its own laboratories, whereby better control over projects is achieved, and later better management of the production<br />
costs. New projects which would be developed in the Hemofarm institute were defined in this sense, with the intention to<br />
register and place them on all markets on which STADA operates.<br />
A visit to the Hemofarm production facilities was organized on the second day, whereby all guests expressed sincere<br />
satisfaction with what they saw. They also praised the excellent organization for which the Hemofarm Institute and the<br />
president’s cabinet were in charge of and expressed a wish to to gather again in our town.<br />
Vjera Pejanović<br />
Hemofarm Institute Director